CRISPR specialist raises $80m in funding

US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Norton Rose Fulbright expands pharma and biotech disputes team

13 February 2026 The firm recruits two Cooley partners with expertise in Hatch-Waxman, BPCIA, trade secrets, and competitor versus competitor patent litigation.

Europe

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

12 February 2026 The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.

Careers

Honigman bags second Kirkland litigator this year for IP team

12 February 2026 New Bloomfield Hills partner handles patent, trade secrets, and contracts disputes, and marks the sixth partner to join the firm in 2026.

More features

New rankings recognise top US patent firms and lawyers

Norton Rose Fulbright expands pharma and biotech disputes team

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

Honigman bags second Kirkland litigator this year for IP team

Reaction: Emotional Perception decision is ‘good for UK PLC’

UK ruling ‘future-proofs’ patentability for AI and computer tech

The curtain closes on three major drug disputes

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

CRISPR specialist raises $80m in funding

More on this story

Editor's picks

Editor's picks

More features